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Background: Chemokines such as MIP-3β/CCL19 are important factors in the mechanism of cell migration and
pathogenesis of central nervous system (CNS) inflammatory reactions. The hypothesis of this study is that CCL19,
also known as MIP-3β, is involved in the pathogenesis of inflammatory and non-inflammatory CNS diseases of dogs.
Experiments were performed on cerebrospinal fluid (CSF) and serum samples of dogs affected with steroid
responsive meningitis-arteritis (SRMA) during the acute phase as well as during treatment. Dogs with SRMA were
compared to dogs with presumed meningoencephalomyelitis of unknown origin (MUO), and both groups
sub-categorized into dogs receiving no therapy and with patients receiving prednisolone therapy. Idiopathic
epilepsy (IE), a group with normal CSF cell count, was used as a control. Additionally, dogs with intervertebral disc
disease (IVDD) of varying severity were analyzed. Chemokine concentrations were determined by enzyme linked
immunosorbent assay. Migration assays were performed on seven selected CSF samples using a disposable 96-well
chemotaxis chamber.
Results: CCL19 was detectable in CSF samples of all dogs. Dogs with untreated SRMA and MUO displayed
pronounced CCL19 elevations compared to the control group and patients receiving glucocorticosteroid treatment.
CSF cell counts of untreated SRMA and MUO patients were significantly positively correlated with the CCL19 CSF
concentration. IVDD patients also had elevated CCL19 concentration compared to controls, but values were
considerably lower than in inflammatory CNS diseases. Selected CSF samples displayed chemotactic activity for
mononuclear cells in the migration assay.
Conclusions: CCL19 CSF concentrations were markedly elevated in patients affected with the neuroinflammatory
diseases SRMA and MUO and showed a strong correlation with the CSF cell count. This chemokine may play an
important role in the pathogenesis of SRMA and MUO. The elevation of CSF CCL19 in IVDD suggests that it may
also be involved in the secondary wave of spinal cord injuries.
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In several neurologic diseases, a pleocytosis is often de-
tected in the cerebrospinal fluid (CSF). Lymphocytes and
plasma cells have been shown to prevail in the cell count in
viral infections [1], chronic steroid responsive meningitis-
arteritis (SRMA) [2], granulomatous meningoencephalo-
myelitis (GME) and in necrotizing encephalitides (NE)
[1,3]. A neutrophilic pleocytosis is characteristic for bac-
terial infections and the acute stage of SRMA [2]. A mixed
cell population can be seen in protozoal diseases, chronic
bacterial infections, necrotic lesions, and in GME [1]. In
addition to inflammatory lesions, mild mixed cell pleocy-
tosis can also be seen with acute intervertebral disc disease
resulting in central nervous system (CNS) myelomalacia
or infarction [4]. Chemokines are important factors in the
mechanism of cell migration and thus play a relevant role
in the pathogenesis of inflammation within the CNS [5].
They up-regulate surface molecules on circulating inflam-
matory cells in the periphery which enable them to more
efficiently adhere to the endothelial cells of the blood–
brain barrier (BBB) and react to the CNS chemokine gra-
dients [6]. One aim of therapeutic research is to develop
specific treatments to modulate the inflammatory re-
sponse within the CNS [7] in diseases such as SRMA and
meningoencephalitides of unknown origin (MUO), and
also modulate inflammation in intervertebral disc diseases
which may be responsible for secondary wave injury
[8-10]. One chemokine that could be involved in the
pathogenesis of an inflammatory reaction and is a compel-
ling candidate for future modulation is (C-C motif) ligand
19 (CCL19), also known as MIP-3β (Macrophage Inflam-
matory Protein- 3 beta). This protein will be referred to as
CCL19 for most of the text of this manuscript but, these
terms may be used interchangeably. CCL19 is constitu-
tively expressed in the CNS for fast immunosurveillance
[11] and is produced by different cells such as dendritic
cells (DC), macrophages and some non-hematopoietic
cells [11,12]. It binds to the CCR7 receptor which is
expressed on myeloid cells [13], mature DC, T cells, as
well as activated B cells [14-16]. CCL19 was suggested
to be involved in the development of chronic inflamma-
tion and lymphoid neogenesis, guiding B cells and T
cells into the target organ, such as the brain [16]. It is
also expressed de novo in various neuroinflammatory
diseases such as multiple sclerosis [11] or chronic ex-
perimental autoimmune encephalomyelitis (EAE) [16,17].
Bone marrow derived microglia or macrophages connect
the brain with the immune system [11,18]. Guiding these
cells to the CNS may also be regulated by CCL19, due
to its role in attracting macrophage progenitors [11,19].
Microglia may produce CCL19 and were shown to be acti-
vated in canine diseases such as MUO [20] and spinal
cord injury [10]. In the current study, our hypothesis is
that protein CCL19 is, at least in part, involved in thepathogenesis of CNS diseases and may be involved in
the invasion of mononuclear cells into the subarachnoid
space of dogs. Therefore, three diseases were chosen:
steroid-responsive meningitis-arteritis (SRMA), menin-
goencephalomyelitis of unknown origin (MUO), and inter-
vertebral disc disease (IVDD). In SRMA, a Th2-mediated
immune response was shown [21,22] and a Th17 skewed
immune response may be accountable for maintaining the
inflammatory reaction [23,24]. For comparison, MUO was
chosen as a disease group with a predominantly mono-
nuclear pleocytosis within the CSF [1,25,26] despite the
heterogeneity of the group. Examples of idiopathic in-
flammatory disorders of the CNS are NE and GME, in
which a strong genetic component [27], occurrence of
autoantibodies [28], and the distribution of lymphocytes
and macrophages [29], suggest a strong involvement of
mononuclear cells in the pathogenesis. A third group
was analyzed. In spinal cord injury involving intervertebral
disc herniation, a local inflammatory reaction has been
documented [30] and the macrophage count within the
CSF is thought to be positively associated with the degree
of spinal cord damage [31]. With this investigation, we
seek to understand the role of CCL19 in the aforemen-
tioned CNS diseases in dogs and establish whether this
chemokine is generally associated with CNS inflammation
or specific to certain diseases.
Methods
Samples from patients and controls
A total of 141 patients were analyzed following referral to
the Department of Small Animal Medicine and Surgery,
University of Veterinary Medicine Hannover, Germany and
the Veterinary Emergency and Specialty Center (VESC)
Santa Fe, NM, USA . The study was approved by the eth-
ics committee of the University for Veterinary Medicine
Hannover. The experimental protocols and procedures
in healthy dogs were performed in accordance with the
European Communities Council Directive of 24 November
1986 (86/609/EEC) and were approved by the author-
ities in Lower Saxony (animal experiment number
33.42502/05-12.05). CSF and serum samples for CCL19
assays were obtained and stored at −20°C. Blood was col-
lected via cephalic, saphenous or jugular venipuncture into
serum tubes. CSF collection was performed under general
anesthesia by cisternal puncture for SRMA, MUO, IE and
healthy dogs or lumbar puncture for IVDD dogs. The CSF
was centrifuged and the sediment was removed. The
remaining CSF was stored at −20°C within 2 hours of sam-
ple collection. Number of patients and their laboratory
findings are provided in Table 1.
SRMA group: Fifty one patients were diagnosed with
SRMA based on clinical signs, complete blood and CSF
examinations, normal cervical radiographs, elevated IgA
levels in CSF and serum, response to glucocorticosteroid
Table 1 CSF and serum characteristics in patients with IE, neuroinflammatory disease, IVDD and clinically healthy patients
SRMA untreated SRMA treated MUO untreated MUO treated IVDD 2/3 IVDD 4/5 Healthy IE (control)*
No. patients 25(5/4/16) 26 16 11 25 11 6 21
CSF cellcount/3microL 528 (200–3800)a 1 (0.25-2) 196 (25.8-73 1.8)b 2 (1–3) 1(1–3) 3 (2.5-4) 1 (0–1)
CSF protein mg/dl 28 (20–55)c 12 (11–14) 40 (25.3-97.3) 16 (14–20) 19(15–22) 14(10.5-16) 12 (10–14)
CSF Ig A 1.6 (0.4-2.7) 0.2 (0.09-0.45)
Serum Ig A 184 (106–282) 75.4 (47.9-98.7)
Blood leucocvtes 20.7 (18–27) 10.9(9.8-13.9) 10.6(9.7-13.1) 10 (9.7-12) 8(7.5-11) 13.2(8.3-15.7) 10(9–12) 10 (9–12)
xl000/microL
CSF CCL19 pg/ml 1690 (671.5-3200)* 'ac 80.5(68–111.5)' 373.5 (174.5-776.8)* ^ b 91.8 (76.695)^ 108.2 (82–162)* d 149.2 (97.6-207)* 51.2 (40.1-54.2)* 66(56–87.1)
Serum CCL19 pg/ml 129.3 (73–198) 84.5(35.5-131.9) 160.6 (79.7-467.9) 51.8 (32.4-190) 146.4 (73–191)d 97.6 (47–129.3) 108.9 (90.4-192) 88.3 (55.8-127)
SRMA = steroid-responsive meningitis-arteritis; MUO =meningoencephalomyelitis of unknown origin; IVDD = intervertebral disc disease; IE = idiopathic epilepsy; Ig = immunoglobulin; No = number; CSF = cerebrospinal
fluid; pg = picogram; microL =microliter; ml = milliliter; mg =milligram; SRMA untreated: n = 25 total; n = 5 one time pre-treated; n = 4 relapse; n = 16 untreated.
*Statistically significant differences, CSF CCL19 comparison SRMA, MUO, IVDD, healthy with IE (control).
'Statistically significant differences, CSF CCL19 comparison SRMA untreated with SRMA treated.
^Statistically significant differences, CSF CCL19 comparison MUO untreated with MUO treated.
aStatistically significant differences, correlation SRMA CSF cell count with CSF CCL19.
bStatistically significant differences, correlation MUO CSF cell count with CSF CCL19.
cStatistically significant differences, correlation SRMA CSF protein with CSF CCL19.
dStatistically significant differences, correlation IVDD CSF CCL19 with Serum CCL19.
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tients which received no medication at the time of sample
collection. Nine of these dogs were evaluated separately,
five patients having received a one-time pre-treatment
with corticosteroids by the referring veterinarian and four
patients having relapsed after stopping previous therapy.
CSF and blood findings are summarized in Table 1. The
SRMA treatment group consisted of 26 of the 51 patients
having received more than one steroid treatment prior to
CSF acquisition.
MUO group: CSF was also obtained from 27 patients
with presumed MUO. Sixteen of these patients received
no therapy (untreated group), while 11 patients were
already being treated with prednisolone (treated group)
(Table 1). The suspected diagnosis was supported by clin-
ical signs, CSF analysis (predominantly mononuclear pleo-
cytosis) and magnetic resonance imaging (MRI) findings
employing T1W, with and without contrast medium,
T2W, and fluid attenuated inversion recovery (FLAIR) se-
quences. In ten patients, the diagnosis was confirmed by
histopathological examination and included four cases of
GME, two of NE and four cases with MUO with a histo-
pathological pattern not related to GME or NE.
IVDD group: The CSF of 36 patients with IVDD was an-
alyzed. The diagnosis of IVDD was made by clinical signs,
CSF analysis, MRI and surgery findings. Based on the se-
verity of clinical signs, the patients were grouped into five
grades [32]. Twenty five patients were combined with the
neurologic status grade 2/3 to one group. The dogs were
mild to severely paretic, but capable of spontaneous
movement. A second group contained 11 patients with
the neurologic status grade 4/5, which were paralyzed
with or without deep pain sensation (Table 1).
Control group: CSF samples with normal reference
values (less than 5 white blood cells/μl, cisternal protein
less than 25 mg/dl) [1] were analyzed. Twenty one pa-
tients were diagnosed with idiopathic epilepsy based on
clinical signs, blood work, MRI and CSF results (Table 1).
IE, a non-inflammatory CNS disease with normal CSF
cell count, was compared to SRMA, MUO and IVDD.
Healthy dogs: Additionally, six samples were obtained
from healthy dogs (Table 1) (Animal Experiment number:
33.42502/05-12.05) and compared to dogs affected with IE
to evaluate differences of CSF CCL19 concentrations be-
tween dogs with normal CSF cell counts.
Measurement of CCL19
Concentrations of CCL19 in the CSF and serum were de-
termined by sandwich ELISA (Enzyme linked immuno-
sorbent assay). An ELISA Kit specific for canine CCL19
(E90096Ca 96 Tests) was used according to manufac-
turer’s instructions (Uscn Life Science Inc., Wuhan, P.R.
China). Briefly, the microtiter plate provided in the ELISA
kit has been pre-coated with a monoclonal antibodyspecific to CCL19. CSF samples were used undiluted or
were diluted to a dilution of 1:13 with the standard diluent
depending on the CCL19 output concentration. Serum
samples were used undiluted for the ELISA. Seven wells
were prepared for the dilutions of standard, one well was
left blank and the rest of the 96 wells were used for the
CSF and serum samples. Four CSF and serum samples of
the IE group served as a control and one of these IE sam-
ples was pipetted to the plates in each experiment. Sam-
ples as a positive control were CSF and serum samples
of the neuroinflammatory group and the same sample
was used in each experiment at same dilution. The color
change was measured spectrophotometrically at a wave-
length of 450 nm ± 10 nm on a microplate reader
equipped with the analysis software Gen 5 (Synergy2
HT multi-mode microplate reader, BioTek Instruments
Inc., Bad Friedrichshall Germany). The detection range
of this method was 15.6 - 1000 pg/ml. The standard
curve was created using a lyophilized standard reagent
(Uscn Life Science Inc., Wuhan, P.R. China) provided in
the ELISA kit. Standard concentrations used for the
ELISA were 1000 pg/ml, 500 pg/ml, 250 pg/ml, 125 pg/ml,
62.5 pg/ml, 31.2 pg/ml, 15.6 pg/ml. The minimum detect-
able dose of canine CCL19 is 6.5 pg/ml. All measurements
of the CSF and serum were performed in duplicates.
Chemotaxis assay
To evaluate chemotactic activity of measured CSF samples
for mononuclear cell migration, assays were performed
using a disposable 96-well chemotaxis chamber with poly-
carbonate filters (5 μm pore size, 3.2 mm diameter size,
30 μl well size) (Chemo TX Disposable Chemotaxis sys-
tem, NeuroProbe, Gaithersburg, MD). CSF samples of
seven patients were examined, three untreated patients di-
agnosed with SRMA, two untreated patients with the sus-
pected diagnosis of MUO and two patients with IVDD.
Peripheral mononuclear cells (PMCs) were separated from
five milliliters of fresh EDTA blood collected via cephalic
venipuncture of a healthy dog. PMCs were separated by
Ficoll gradient centrifugation according to the technique
described by Toth et al. 1992 [33]. PMCs were washed
twice with ten milliliters Hank’s balanced salt solution
(HBSS) (Fa. Sigma-Aldrich, Deisenhofen, Germany) and
re-suspended in Cell-Wash fluid (Becton Dickinson,
Heidelberg, Germany). The cell suspension was stained by
trypanblue (0.4% in phosphate buffered saline (PBS) Fa.
Sigma-Aldrich, Schnelldorf, Germany) and counted in a
TURK cell counting chamber (Fa. Brand, Wertheim,
Germany). Twenty five microliters of the cell suspension
(50000 cells/25 μl) were pipetted directly on the top side
of the filter, which is coated with a hydrophobic mask
around each of the test sites. The hydrophobic mask re-
stricts the cell suspension to these sites, eliminating the
need for upper wells. A known serial dilution of the cell
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6250 cells, 3125 cells, 1563 cells and 781 cells diluted in
medium was pipetted in one row of wells to serve as a
standard with which to compare the readings from the
experimental wells. The rest of the 96 wells were loaded
in duplicates with 29 μl of SRMA (untreated n = 3),
IVDD (n = 2) and MUO (untreated n = 2) CSF samples
diluted in equal volume in Rosewell Park Memorial In-
stitute (RPMI)1640 medium with L-glutamine (Gibco®
RPMI Media 1640) containing 1% bovine serum albu-
min (BSA) and a negative control of pure medium. The
loaded chamber with added cell suspension on the top
side of the filter was cultured at 37°C in humidified air
with 5% CO2 in an incubator (SANYO Sales & Marketing
Europe GmbH, Munich) while the migration time for
the cell suspension was measured at 30 minutes, 1 hour,
1.5 hours and 2 hours. The filter was removed and cells
that had migrated through the filter to the lower wells
were counted by alamarBlue® assay (Serotec, Düsseldorf,
Germany). AlamarBlue® reagent was added as 10% of the
sample volume, followed by 1 to 3 hours incubation at
37°C. Resazurin, the active ingredient of alamarBlue® re-
agent, is a non-toxic, cell permeable compound that is
blue in color and virtually non-fluorescent. Upon entering
cells, resazurin is reduced by viable cells to resorufin, aFigure 1 CCL19 CSF concentrations of patients with IE and healthy an
boxes indicate median values, endpoints of vertical lines display minimum an
significant differences (*P < 0.05; **P < 0.01; ***P < 0.005). IE = idiopathic epilepcompound that is red in color and highly fluorescent. The
resulting fluorescence was read on a microplate reader
equipped with the analysis software Gen 5 (Synergy2 HT
multi-mode microplate reader, BioTek Instruments Inc.,
Bad Friedrichshall Germany).
Statistics
For group comparison, the Kruskal-Wallis test and the
Mann–Whitney–Wilcoxon tests were used. Using the
Shapiro-Wilk test, an abnormal data distribution was
found. Correlation between two variables were tested by
Spearman and Kendall rank correlation tests. Statistical
significance was set at the 5% level (P < 0.05).
Results
CCL19 concentration in CSF of the control group
(idiopathic epilepsy) and healthy dogs
CCL19 was measurable in all 21 samples of patients with
idiopathic epilepsy and in the 6 samples from healthy do-
nors (Table 1). The comparison between IE and healthy
animals showed significant difference (p = 0.0488) which is
shown in Figure 1. Although there were significant differ-
ences detected between samples from dogs with IE and
from healthy animals, IE is considered as the control
group due to normal CSF examinations and normal CSFimals. Boxes contain values from the 1st to the 3rd quartile, lines inside
d maximum values, o represents the outliers. Asterisks indicate statistically
sy; CSF = cerebrospinal fluid; pg = picogram; ml =milliliter.
Figure 2 CCL19 CSF concentrations of patients with SRMA compared to the control group. y- axis: logarithm to base 10 of CCL19 (pg/ml);
x- axis: groups. Boxes contain values from the 1st to the 3rd quartile, lines inside boxes indicate median values, endpoints of vertical lines display
minimum and maximum values, o represents the outliers. Asterisks indicate statistically significant differences (*P < 0.05; **P < 0.01; ***P < 0.005).
SRMA = steroid-responsive meningitis-arteritis; CSF = cerebrospinal fluid; IE = idiopathic epilepsy.
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group IE was 66 pg/ml. Healthy dogs had a median CSF
CCL19 concentration of 51.2 pg/ml (Table 1). The signifi-
cant difference between IE and healthy dogs suggests that
CCL19 might be involved in the pathway of IE. Since only
a small number of neurologically normal dogs was avail-
able for evaluation, further studies with a larger cohort of
dogs focusing on IE in comparison to healthy dogs are
indicated.
CCL19 CSF concentration in inflammatory diseases
Significantly elevated CCL19 concentrations were observed
in CSF samples of untreated SRMA and MUO patients
compared to the control group (IE) (p < 0.001; median
SRMA: 1690 pg/ml; MUO: 373.5 pg/ml) as shown in
Figure 2, Figure 3, and Table 1. Dogs that had under-
gone therapy had significantly lower CCL19 values
compared to the patients without therapy (p < 0.001).
Treated SRMA dogs (p = 0.1427) and treated MUO pa-
tients (p = 0.1368) did not differ significantly from the
controls. SRMA patients, which received one injection
of glucocorticosteroids before initial examination, had
significantly lower CCL19 levels (p = 0.0259) compared
to entirely untreated animals. The subgroup of patientshaving a relapse did not differ statistically (p = 0.4864)
from untreated patients (Figure 2 and Figure 3).
Further evaluation of inflammatory diseases
The CSF CCL19 concentrations of both untreated SRMA
and untreated MUO patients were significantly correlated
with the CSF cell count (SRMA r = 0.82, p < 0.001; MUO
r = 0.59, p = 0.018).
SRMA and MUO patients under glucocorticosteroid
treatment displayed no correlation between CSF cell count
and CCL19 concentration as indicated by the results of
Spearman and Kendall’s rank test (Spearman: SRMA r =
0.27, p = 0.19; MUO r = 0.53, p = 0.091). The CSF CCL19
and serum CCL19 concentrations did not correlate with
each other indicating that CSF elevation is not due, at least
entirely, to BBB disruption (Spearman: SRMA untreated
r = 0.099, p = 0.64; MUO untreated r = 0.33, p = 0.22). Total
protein levels within the CSF from untreated SRMA dogs
had a weak correlation with CSF CCL19 concentrations
using Spearman rank test (r = 0.39, p = 0.055); the Kendall
rank test was performed due to the occurrence of outliers
and revealed a significant correlation (tau = 0.33, p =
0.022). Dogs with MUO that did not receive therapy
had no strong correlation between CCL19 CSF and
Figure 3 CCL19 CSF concentrations of patients with MUO compared to the control group. y- axis: logarithm to base 10 of CCL19 (pg/ml);
x- axis: groups. Boxes contain values from the 1st to the 3rd quartile, lines inside boxes indicate median values, endpoints of vertical lines display
minimum and maximum values, o represents the outliers. Asterisks indicate statistically significant differences (*P < 0.05; **P < 0.01; ***P < 0.005).
MUO =meningoencephalomyelitis of unknown origin; CSF = cerebrospinal fluid; IE = idiopathic epilepsy.
Figure 4 CCL19 CSF concentrations of patients with IVDD
compared to the control group. Boxes contain values from the
1st to the 3rd quartile, lines inside boxes indicate median values,
endpoints of vertical lines display minimum and maximum values,
o represents the outliers. Asterisks indicate statistically significant
differences (*P < 0.05; **P < 0.01; ***P < 0.005). IVDD = intervertebral
disc disease; CSF = cerebrospinal fluid; IE = idiopathic epilepsy.
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Kendall: tau = 0.33, p = 0.079).
CCL19 CSF concentration in intervertebral disc disease
CSF CCL19 concentrations of IVDD are significantly el-
evated compared to the control group (p <0.05) as illus-
trated in the Box-and-Whisker Plots in Figure 4. The
median concentration of the protein in the IVDD grade
2/3 group was 108.2 pg/ml while grades 4/5 had a
higher median of 149.2 pg/ml, as compared to the con-
trols with a median concentration of 66 pg/ml (Table 1).
The concentrations between the two IVDD groups did
not differ significantly (p = 0.26). In comparison to the
median CCL19 concentrations from untreated inflam-
matory neurologic diseases (SRMA: 1690 pg/ml/MUO:
373.5 pg/ml) the elevations were mild (Figures 2, 3
and 4).
Further evaluation of IVDD
No significant correlation of CSF CCL19 concentrations
to CSF cell count was found among the IVDD group
(Spearman: IVDD group 2/3 r = 0.05, p = 0.81; IVDD
group 4/5 r 0.097, p = 0.78). CCL19 CSF concentration
and CCL19 serum concentration were significantly cor-
related within IVDD group 2/3 (r = 0.44, p = 0.025) while
IVDD group 4/5 had no significant correlation (r = 0.54,
p = 0.094).
Figure 5 Chemotaxis assay for mononuclear cells from CSF samples of SRMA, MUO, IVDD, medium. Vertical lines indicate standard
deviation. SRMA = steroid responsive meningitis-arteritis; MUO =meningoencephalomyelitis of unknown origin; IVDD = intervertebral disc disease;
CSF = cerebrospinal fluid; pg = picogram; ml =milliliter.
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mononuclear cells
CSF samples were used to induce mononuclear cell
chemotactic activity. CSF of neuroinflammatory diseases,
including SRMA and MUO, showed high cell migration
as illustrated in Figure 5. The SRMA samples with a
mean concentration of 3892.33 pg/ml CCL19 attracted
24083 cells and the MUO samples with a mean concen-
tration of 1831 pg/ml CCL19 attracted 23876 cells after
a two hour period, which was significantly more than
the control group (medium 10785 cells). The CSF sam-
ples of dogs with IVDD with a much lower mean CCL19
concentration of 208.5 pg/ml compared to neuroinflam-
matory diseases also had a significant impact on migra-
tion and on average 17235 cells moved to the lower
chamber after a 2 hour incubation time (Figure 5).
Discussion
The results of this study support the hypothesis that the
protein CCL19 is elevated in selected CNS diseases and
might be involved in the pathogenesis of mononuclear
cells migration into the subarachnoid space of dogs with
inflammatory CNS diseases and non-inflammatory CNS
diseases such as intervertebral disc disease (IVDD). CSF
levels of the chemokine CCL19 were analyzed in dogs
afflicted with SRMA, an inflammatory CNS disease, and
compared to other neuroinflammatory diseases (MUO),
traumatic IVDD, a non-inflammatory CNS disease, idio-
pathic epilepsy (IE) and normal unafflicted animals.
CCL19 was detectable in healthy dogs and in patients
with idiopathic epilepsy, a non-inflammatory neurologic
disease, which is in agreement with the results of other
studies [11,16] in that CCL19 is constitutively expressed in
the CNS and linked to the physiological immunosurveil-
lance [11,16]. However, CCL19 was markedly increasedin both neuro- inflammatory diseases SRMA and MUO
(Figure 2 and 3). Thus, CCL19 might be involved in the
pathogenesis of CNS inflammation and in the migration of
inflammatory cells into the subarachnoid space. Krumbholz
et al. [11] and Pashenkov et al. [16] observed a CSF
CCL19 elevation in neuro- inflammatory diseases of hu-
man patients. Earlier observations have shown that
CCL19 is also produced by neutrophils [34]. The higher
concentration of the chemokine in SRMA is consistent
with the fact that SRMA CSF has an increased neutro-
philic inflammatory response. The elevated chemokine
concentration may maintain the inflammatory response
and later transfer to an autoimmune reaction attracting
certain lymphocyte subsets. Additionally, a disrupted
blood brain barrier is consistent with a strong inflam-
matory response and could support the explanation for
much higher CCL19 data. However, CCL19 levels were
higher in CSF samples compared to serum concentrations
in neuroinflammatory diseases suggesting intrathecal pro-
duction rather than passive diffusion through a disrupted
blood brain barrier. Results of Pelletier et al.’s study
revealed that a novel chemokine-dependent reciprocal
cross-talk between neutrophils and Th17 cells exists [35].
Activated neutrophils induced chemotaxis of Th17 cells
and in turn could attract more neutrophils [35]. Observa-
tions from Maiolini hint that the immunopathology of
SRMA is maintained by a Th17 response [23]. Neutrophils
can release a number of chemokines including CCL19,
which can specifically induce chemotaxis of dendritic cells
(DC) and trigger rapid integrin-dependent adhesion of
CCR7-expressing lymphocytes [34]. The neutrophil’s cap-
ability of CCL19 production might be important in guid-
ing these cells to the inflamed sites and contributing to
the regulation of the immune response. It has been shown
previously that CCR7 ligands like CCL19 have a function
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pathogenic Th17 cells in EAE induction [36]. An uncon-
trolled interleukin (IL) IL-23–IL-17 pathway could main-
tain a chronic inflammatory response and lead to persistent
immunopathology [24]. Investigating this relationship and
uncovering other similar pathways could be vital to our un-
derstanding of the pathogenesis of chronic inflammatory
diseases. The intrathecally produced CCL19 might not only
play a role in inducing autoimmune diseases but also in
maintaining chronic forms through recruitment of antigen
presenting cells and lymphocytes, resulting in perpetual
antigenic stimulation [37]. Guinti et al. also observed sig-
nificant levels of CCL19 in patients affected with MS and
patients affected with other neuroinflammatory diseases
and suspect involvement in T-cell trafficking [38]. In our
study, the strong correlation between intrathecal CCL19
and the CSF cell count suggest CCL19 may play an import-
ant role in recruiting immune cells to the CNS.
SRMA and MUO patients receiving glucocorticoster-
oids had significantly less CCL19 concentrations, show-
ing that steroids have a strong impact in reducing the
inflammatory pathway. Krumbholz et al.’s study did not
reveal that MS patients receiving treatment differ from
untreated patients [11]. Glucocorticosteroids are shown
to reduce the invasion of neutrophils [39] and may alter
the production of chemokines in dogs. Relapsing SRMA
also displayed elevated chemokine concentrations. This
finding suggests the potential utility of this protein for
developing new treatment schemes in inflammatory dis-
eases, and to indicate the success of treatment.
The elevation of CCL19 in IVDD CSF suggests a process
of a secondary inflammatory response within the CNS
[40]. Gray and white matter are affected by trauma, espe-
cially when white matter damage is observed [30,41]
through apoptosis, necrosis, and inflammation. Increased
inflammatory cytokines in patients with chronic spinal
cord injury after trauma suggest an altered immunological
activation. A study by Srugo et al. suggested CSF pleocyto-
sis is positively associated with the severity of thoracolum-
bar spinal cord damage in dogs with IVDD. They found
that the percentage of CSF macrophages can be used as a
prognostic indicator for regaining ambulation in dogs that
have lost deep pain sensation [31]. The current study ad-
dresses the question if CCL19 could also play an import-
ant role for the migration of cells and the inflammatory
pathogenesis in IVDD. A modest correlation of CSF to
serum CCL19 in IVDD group 2/3 suggest that CSF
CCL19 is derived by leakage via extracellular pathways
from the circulation and not solely from intrathecal pro-
duction in this group of patients. However, no correlation
was found in between CSF and serum CCL19 concentra-
tions in IVDD group 4/5 and some samples showed much
higher CSF values suggesting the likelyhood of intrathecal
production. A set of chemokines is intrathecally producedin CNS diseases leading to an inflammatory response. The
fact that CCL19 is significantly elevated but, did not cor-
relate with CSF cell count in either IVDD group suggests
that CCL19 is not solely responsible for the recruitment of
cells but, may play a part in the pathogenesis of IVDD
inflammation.
The performed chemotaxis assay from CSF samples
attracted mononuclear cells. CSF of neuro-inflammatory
diseases showed strong chemotactic activity in comparison
to the controls. Even CSF samples of dogs with IVDD with
a much lower mean CCL19 concentration showed a pro-
nounced impact on cell migration, which suggests the pre-
sents of a functional chemotactic protein. Alt et al.
showed that the expression of CCL19 occurs at the BBB
in experimental autoimmune encephalomyelitis and con-
cluded that this chemokine may contribute to T -cell at-
traction across the BBB [42]. CSF consists of various sets
of chemokines responsible for cell migration. A chemo-
taxis study using a CCL19 antagonist may prove to be use-
ful in defining CCL19’s role in mononuclear cell migration
into the CNS of SRMA, MUO and IVDD dogs. A study
from Pineau and Lacroix on rodent models revealed that
cytokine production is time dependent [43]. CNS resident
cells, including neurons, synthesized cytokines between 3
and 24 hours post SCI and some infiltrating leukocytes
were responsible for the cytokine production 12 hours
after the trauma. This would suggest that neural cells are
responsible for the initial inflammatory response following
SCI but, the recruitment of additional immune cells is
responsible for the maintenance of inflammation [43].
Additional studies would be necessary to determine the
time at which CCL19 becomes a major inflammatory me-
diator. Kwon et al. observed in his study that interleukin
(IL)-6, IL-8, tau, S100b and glial fibrillary acidic protein
were elevated depending on severity of the initial injury.
Evaluating this group of inflammatory cytokines, a bio-
chemical model was developed enabling veterinary sci-
entists to predict the ASIA (American Spinal Injury
Association) grade in 89% of their subjects. It was found
that the pattern of protein expression within the CSF
over the first few days following injury were strong indi-
cators of neurologic outcome and thus, are now a focus
of therapeutic research for SCI [44]. Using CCL19 CSF
concentration as a prognostic marker could be also
helpful in the research of SCI in dogs, which should be
followed up in further studies.
Conclusions
In conclusion, CCL19 CSF concentrations were mark-
edly elevated in patients with neuroinflammatory disease
and may play an important role in their pathogenesis
with recruitment of inflammatory cells into the sub-
arachnoid space of dogs. This study also showed an ele-
vated CSF CCL19 concentration in dogs with IVDD,
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with the secondary wave of SCI, following an acute cord in-
sult. A marked chemotactic activity for mononuclear cells
was observed in selected CSF samples of the neuroinflam-
matory and non-neuroinflammatory disease. Further func-
tional studies could confirm that CCL19 has a major role
of mononuclear cell migration into the subarachnoid space
of dogs affected with SRMA, MUO, IVDD and may be a
precious target for developing new treatment schemes.
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